Immunoglobulins (IGs), also known as antibodies, are glycoproteins produced by the blood plasma in response to foreign bodies or antigens. They are highly complex entities and are specific in their action. These IGs are obtained from blood through the process of fractionation and are purified for use in therapeutic and non-therapeutic areas. The global intravenous immunoglobulin (IGIV) market was valued at $7,861 million in 2015 and is projected to reach $12,632 million by 2022, registering a CAGR of 7.1% from 2016 to 2022. Research Beam Model: Research Beam Product ID: 3320694 5370 USD New
Intravenous Immunoglobulin (IVIG) Market by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain - Barre Syndrome, and Others) and Type (IgG, IgA, IgM, IgE, and IgD: Global Opportunity Analysis and Industry Forecast, 2016 - 2022
 
 

Intravenous Immunoglobulin (IVIG) Market by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain - Barre Syndrome, and Others) and Type (IgG, IgA, IgM, IgE, and IgD: Global Opportunity Analysis and Industry Forecast, 2016 - 2022

  • Category : Pharmaceuticals
  • Published On : November   2018
  • Pages : 220
  • Publisher : Allied Market Research
 
 
 

Intravenous Immunoglobulin (IVIG) Market Overview:

Immunoglobulins (IGs), also known as antibodies, are glycoproteins produced by the blood plasma in response to foreign bodies or antigens. They are highly complex entities and are specific in their action. These IGs are obtained from blood through the process of fractionation and are purified for use in therapeutic and non-therapeutic areas. The global intravenous immunoglobulin (IGIV) market was valued at $7,861 million in 2015 and is projected to reach $12,632 million by 2022, registering a CAGR of 7.1% from 2016 to 2022.
 
Increase in prevalence of immunodeficiency and autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia & others and rise in adoption of immunoglobulin treatments for the treatment of various autoimmune disorders majorly drive the growth of the IVIG market. Further, the increase in approval of IVIG drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and other government agencies is expected to accelerate the market growth of IVIG industry. However, stringent government regulations, inflated cost of therapy, and high risk of side effects associated with the use of immunoglobulin intravenously are anticipated to hamper the market growth. On the contrary, significant investment in healthcare sector is expected to provide lucrative opportunities for the market growth in the near future.

The global IVIG market is characterized based on application, type, and region. Based on application, the market is segmented into hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, Guillain–Barre syndrome, and others. Based on type, the market is classified into IgG, IgA, IgM, IgE, and IgD. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits for Intravenous Immunoglobulin (IVIG) Market:

  • The report provides an in-depth analysis of the intravenous immunoglobulin market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in this study.
  • The report provides a detailed quantitative analysis of the industry from 2016 to 2022 to assist stakeholders to capitalize on the prevailing market opportunities.
  • An extensive analysis of the key segments of the industry helps to understand the trends in the intravenous immunoglobulin market globally.
  • Key players and their strategies are provided to understand the competitive outlook of the industry.

Intravenous Immunoglobulin (IVIG) Key Market Segments:

By Application

  • Hypogammaglobulinemia
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Primary Immunodeficiency Disease
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Inflammatory Myopathies
  • Specific Antibody Deficiency
  • Guillain–Barre Syndrome
  • Others

By Type

  • IgG
  • IgA
  • IgM
  • IgE
  • IgD

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • France
    • Austria
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Africa
    • Middle East

Key Players Profiled

  • Baxter international Inc.
  • CSL Ltd.
  • Grifols, S.A.
  • Octapharma AG
  • Kedrion Biopharma Inc.
  • LFB group
  • Biotest AG
  • China Biologics Products, Inc.
  • Shire Plc.(Baxalta)
  • Bayer AG

The other players of the intravenous immunoglobulin market include (companies not profiled in the report):

  • Hualan Biological Engineering Inc.
  • Omrix Biopharmaceuticals Ltd.
  • Behring GmbH
  • Shanghai RAAS Blood Products Co., Ltd.
  • Option Care Enterprises, Inc.
  • ADMA Biologics, Inc.
  • BioScrip, Inc.

Chapter: 1. INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS:
1.3. KEY MARKET SEGMENTS:
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst tools and models

Chapter: 2. EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3. MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. OVERVIEW OF IVIG

3.2.1. Patented products

3.3. EPIDEMIOLOGY AND ECONOMIC BURDEN OF CHRONIC CONDITIONS
3.4. COST OF SIDE EFFECTS DUE TO IVIG TREATMENTS
3.5. KEY FINDINGS

3.5.1. Top Factors Impacting global IVIG market
3.5.2. Top Investment Pockets Global IVIG Market

3.6. PORTERS FIVE FORCES ANALYSIS

3.6.1. Bargaining power of buyers (Low)
3.6.2. Bargaining power of suppliers (Low)
3.6.3. Threat of new entrants (low)
3.6.4. Threat of substitutes (low)
3.6.5. Intense competitive rivalry (moderate)

3.7. VALUE CHAIN ANALYSIS

3.7.1. Primary activities
3.7.2. Support Activities

3.8. MARKET SHARE ANALYSIS (2014)
3.9. PRODUCT SCENARIO IN IVIG MARKET
3.10. GOVERNMENT REGULATIONS AND REIMBURSEMENTS

3.10.1. IVIG regulations in United States and Europe
3.10.2. Reimbursements Scenario

3.11. INDICATIONS FOR IVIG

3.11.1. USFDA Indications
3.11.2. EMA

3.12. COMPONENT ANALYSIS OF IMMUNOGLOBULIN G (IGG)

3.12.1. IgG1
3.12.2. IgG2
3.12.3. IgG3
3.12.4. IgG4

3.13. CLINICAL TRIALS
3.15. MARKET DYNAMICS

3.15.1. Drivers
3.15.2. Restraints
3.15.3. Opportunities

Chapter: 4. IVIG MARKET, BY APPLICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. HYPOGAMMAGLOBULINEMIA

4.2.1. Market size and forecast

4.3. CIDP

4.3.1. Market size and forecast

4.4. IMMUNODEFICIENCY DISEASES

4.4.1. Market size and forecast

4.5. MYASTHENIA GRAVIS

4.5.1. Market size and forecast

4.6. MULTIFOCAL MOTOR NEUROPATHY

4.6.1. Market size and forecast

4.7. PRIMARY ITP

4.7.1. Market size and forecast

4.8. INFLAMMATORY MYOPATHIES

4.8.1. Market size and forecast

4.9. SAD

4.9.1. Market size and forecast

4.10. GBS

4.10.1. Market size and forecast

4.11. OTHERS

4.11.1. Market size and forecast

Chapter: 5. IVIG MARKET BY PRODUCT TYPES

5.1. IGG

5.1.1. Key Market Trends
5.1.2. Clinical Interpretations

5.2. IGA

5.2.1. Key Market Trends
5.2.2. Clinical interpretation

5.3. IGM

5.3.1. Key Market Trends
5.3.2. Clinical Interpretation

5.4. IGE

5.4.1. Key Market Trends
5.4.2. Clinical Interpretation

5.5. IMMUNOGLOBULIN D (IGD)

5.5.1. Key Market Trends

Chapter: 6. IVIG MARKET, BY GEOGRAPHY

6.1. Market size and forecast
6.2. NORTH AMERICA

6.2.1. U.S.

6.2.1.1. U.S. Market size and forecast

6.2.2. Canada

6.2.2.1. Market size and forecast

6.2.3. Mexico

6.2.3.1. Market Size and forecast

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Market size and forecast
6.3.3. U.K.

6.3.3.1. Market size and forecast

6.3.4. France

6.3.4.1. Market size and forecast

6.3.5. Germany

6.3.5.1. Market size and forecast

6.3.6. Italy

6.3.6.1. Market size and forecast

6.3.7. Austria

6.3.7.1. Market size and forecast

6.3.8. Russia

6.3.8.1. Market size and forecast

6.3.9. Other countries

6.3.9.1. Market size and forecast

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Market size and forecast
6.4.3. Australia

6.4.3.1. Market size and forecast

6.4.4. China

6.4.4.1. Market size and forecast

6.4.5. Japan

6.4.5.1. Market size and forecast

6.4.6. India

6.4.6.1. Market size and forecast

6.4.7. Others

6.4.7.1. Market size and forecast

6.5. LAMEA

6.5.1. Key Market Trends
6.5.2. Market size and forecast
6.5.3. Latin America

6.5.3.1. Market size and forecast

6.5.4. Africa

6.5.4.1. Market size and forecast

6.5.5. Middle East

6.5.5.1. Market size and forecast

Chapter: 7. COMPANY PROFILES

7.1. BIOTEST AG

7.1.1. Company Overview
7.1.2. Biotest AG: Company Snapshot
7.1.3. Operating business segments
7.1.4. Business performance
7.1.5. Key Strategic Moves & Developments

7.2. OCTAPHARMA AG

7.2.1. Company Overview
7.2.2. Octapharma AG: Company Snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key Strategic Moves & Developments

7.3. BAXTER INTERNATIONAL INC.

7.3.1. Company Overview
7.3.2. Baxter International, Inc.: Company Snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.3.5. Key Strategic Moves & Developments

7.4. LFB BIOTECHNOLOGIES

7.4.1. Company Overview
7.4.2. LFB Biotechnologies: Company Snapshot
7.4.3. Operating business segments
7.4.4. Business performance
7.4.5. Key Strategic Moves & Developments

7.5. CHINA BIOLOGICS PRODUCTS INC.

7.5.1. Company overview
7.5.2. China Biologic Products Inc. Snapshot
7.5.3. Operating business segment overview
7.5.4. Financial performance
7.5.5. Key Strategic Moves & Developments

7.6. GRIFOLS S.A.

7.6.1. Company overview
7.6.2. Grifols S.A Snapshot
7.6.3. Operating Business Segment Overview
7.6.4. Financial performance
7.6.5. Strategic moves and developments

7.7. KEDRION BIOPHARMA

7.7.1. Company overview
7.7.2. Kedrion Biopharma. Snapshot
7.7.3. Operating business segment overview
7.7.4. Financial performance
7.7.5. Strategic moves and developments

7.8. CSL BEHRING

7.8.1. Company overview
7.8.2. CSL Behring Snapshot
7.8.3. Operating business segment overview
7.8.4. Financial performance
7.8.5. Strategic moves and developments

7.9. BDI PHARMA INC.

7.9.1. Company overview
7.9.2. BDI pharma Inc. Snapshot
7.9.3. Operating business segment overview
7.9.4. Strategic moves and developments

7.10. BAYER HEALTHCARE

7.10.1. Company overview
7.10.2. Business performance
7.10.3. Strategic moves and developments

LIST OF TABLES

TABLE 1. IVIG PRODUCTS COMMERCIALIZED IN MARKET
TABLE 2. USFDA INDICATIONS FOR IVIG
TABLE 3. EMA APPROVED INDICATIONS FOR IVIG
TABLE 4. IGG SUBCLASS
TABLE 5. FREQUENCY (%) OF DECREASED IGG SUBCLASS CONCENTRATION IN ADULTS
TABLE 6. DISEASE ASSOCIATE WITH IGG SUBCLASS DEFICIENCY
TABLE 7. CLINICAL TRIALS FOR IVIG (2011-2014)
TABLE 8. GLOBAL IVIG MARKET, BY APPLICATION, 2014-2022,($MILLION)
TABLE 9. GLOBAL IVIG MARKET, BY APPLICATION, 2014-2022, (TON)
TABLE 10. COMMON MEDICATION FOR THE HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH RECURRENT BACTERIAL INFECTIONS
TABLE 11. HYPOGAMMAGLOBULINEMIA IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 12. CIDP IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 13. PRINCIPLE OF IVIG THERAPY IN IMMUNODEFICIENCY
TABLE 14. IMMUNODEFICIENCY DISEASES IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 15. MYASTHENIA GRAVIS IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 16. MMN IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 17. ITP TREATMENT OPTIONS
TABLE 18. ITP IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 19. INFLAMMATORY MYOPATHIES IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 20. SAD IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 21. GBS IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 22. OTHER IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 23. GLOBAL IVIG MARKET BY GEOGRAPHY, 2014-2022, ($MILLION)
TABLE 24. GLOBAL IVIG MARKET BY GEOGRAPHY, 2014-2022, (TON)
TABLE 25. NORTH AMERICA IVIG MARKET, BY COUNTRY, 2014-2022, ($ MILLION)
TABLE 26. NORTH AMERICA IVIG MARKET, BY COUNTRY, 2014-2022, (TON)
TABLE 27. U.S. IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 28. CANADA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 29. MEXICO IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 30. EUROPE IVIG MARKET, BY COUNTRY, 2014-2022, ($ MILLION)
TABLE 31. EUROPE IVIG MARKET, BY COUNTRY, 2014-2022, (TON)
TABLE 32. U.K. IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 33. FRANCE IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 34. GERMANY IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 35. ITALY IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 36. AUSTRIA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 37. RUSSIA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 38. OTHER IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 39. ASIA-PACIFIC IVIG MARKET, BY COUNTRY, 2014-2022, ($MILLION)
TABLE 40. ASIA-PACIFIC IVIG MARKET, BY COUNTRY, 2014-2022, (TON)
TABLE 41. AUSTRALIA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 42. CHINA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 43. JAPAN IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 44. INDIA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 45. OTHER IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 46. LAMEA IVIG MARKET, BY COUNTRY, 2014-2022, ($ MILLION)
TABLE 47. LAMEA IVIG MARKET, BY COUNTRY, 2014-2022, (TON)
TABLE 48. LATIN AMERICA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 49. AFRICA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 50. MIDDLE EAST IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 51. OPERATING BUSINESS SEGMENT OVERVIEW
TABLE 52. OPERATING BUSINESS SEGMENT OVERVIEW
TABLE 53. CHINA BIOLOGIC PRODUCTS INC. SNAPSHOT
TABLE 54. CHINA BIOLOGIC PRODUCTS INC. OPERATING BUSINESS SEGMENT OVERVIEW
TABLE 55. GRIFOLS S.A SNAPSHOT
TABLE 56. GRIFOLS S.A OPERATING SEGEMENTS
TABLE 57. KEDRION INC. SNAPSHOT
TABLE 58. KEDRION BIOPHARMA OPERATING SEGMENTS
TABLE 59. CSL BEHRING SNAPSHOT
TABLE 60. CSL BEHRING OPERATING SEGMENTS
TABLE 61. BDI PHARMA INC SNAPSHOT
TABLE 62. BDIPHARMA OPERATING SEGMENTS
TABLE 63. BAYER HEALTHCARE COMPANY SNAPSHOT

LIST OF FIGURES

FIGURE 1. PERCENTAGE SHARE OF COST ASSOCIATED WITH SIDE EFFECTS INDUCED BY IVIG THERAPY
FIGURE 2. TOP FACTORS IMPACTING GLOBAL IVIG MARKET (20152021)
FIGURE 3. TOP INVESTMENT POCKETSGLOBAL IVIG MARKET
FIGURE 4. PORTERS FIVE FORCES ANALYSIS
FIGURE 5. VALUE CHAIN ANALYSIS OF GLOBAL IVIG MARKET
FIGURE 6. MARKET SHARE ANALYSISGLOBAL IVIG MARKET 2014
FIGURE 7. BIOTEST AG: REVENUE, 2013-2015, ($MILLION)
FIGURE 8. BIOTEST AG: REVENUE, BY SEGMENT, 2015 (%)
FIGURE 9. BIOTEST AG: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 10. OCTAPHARMA AG:REVENUE, 2013-2015, ($MILLION)
FIGURE 11. BAXTER INTERNATIONAL, INC.:REVENUE, 2013-2015, ($MILLION)
FIGURE 12. BAXTER INTERNATIONAL, INC.:REVENUE, BY BUSINESS SEGMENT, 2015 (%)
FIGURE 13. BAXTER INTERNATIONAL, INC.: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 14. LFB BIOTECHNOLOGIES: REVENUE, 2013-2015, ($MILLION)
FIGURE 15. LFB BIOTECHNOLOGIES: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
FIGURE 16. LFB BIOTECHNOLOGIES: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 17. CHINA BIOLOGIC PRODUCTS INC: REVENUE, 2013-2015, ($MILLION)
FIGURE 18. CHINA BIOLOGIC PRODUCTS INC. FINANCIAL PERFORMANCE, BY SEGMENTS, (2015)
FIGURE 19. GRIFOLS S.A: REVENUE, 2013-2015, ($MILLION)
FIGURE 20. FINANCIAL OF GRIFOLS S.A, BY GEOGRAPHY, (2015)
FIGURE 21. FINANCIAL GRIFOLS S.A., BY PRODUCT GROUPS, (2015)
FIGURE 22. KEDRION BIOPHARMA: REVENUE, 2013-2015, ($MILLION)
FIGURE 23. FINANCIAL REVENUE OF KEDRION BIOPHARMA GEOGRAPHY (2015)
FIGURE 24. CSL BEHRING: REVENUE, 2013-2015, ($MILLION)
FIGURE 25. CSL BEHRING FINANCIAL REVENUE OF BY GEOGRAPHY (2013)
FIGURE 26. CSL BEHRING FINANCIAL REVENUE OF BY BUSINESS GROUP (2013)
FIGURE 26. CSL BEHRING FINANCIAL REVENUE OF BY BUSINESS GROUP (2013)
FIGURE 27. FINANCIAL REVENUE OF BAYER HEALTHCARE 2013-2015
FIGURE 28. FINANCIALS OF BAYER HEALTHCARE, BY SEGMENTS, 2015
FIGURE 29. FINANCIALS OF BAYER HEALTHCARE, BY REGIONS, 2015

PURCHASE OPTIONS
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 

Related Reports

Global Heparin Market Research Report 2019

Published On : January   2019

$ 2900

$ 2900

REQUEST SAMPLE    ASK FOR DISCOUNT